Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR103 Calcium in HER2-positive Advanced Gastric/GEJ Adenocarcinoma (BHARAT-2)
NCT07040059Phase 2Terminated
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AUR103 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Aurigene Pharmaceutical Services Limited. Started Mar 2025; status: terminated.
02
Drugs
AUR103
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07040059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040059.